Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer’s Read Criticizes Rebates Amid Changing Market Dynamics

Executive Summary

Pfizer CEO Ian Read suggested it might be time for a new solution that would allow the pharma industry to moderate pricing based on volume without relying on rebates, criticizing a practice he said has become “less helpful” in getting cost effective solutions to patients.


Related Content

Where Will It End? Lilly’s US Price Concessions Increase 30% In 2016
Medicaid Reform And Rebates: State “Opt-Out” Proposed At Hearing
US Drug Spending: Where Does All The Money Go?
Price Rebates Will Continue As ‘Fact Of Life’ In Drug Contracting
Drug Affordability Review By National Academies Kicks Off With Lower Profile Than Expected
US Brand Drug Price Inflation Slowing As Elections Approach
Industry Sounds Somewhat Muted Drug Pricing Alarm
Pfizer’s Bococizumab Discontinuation Increases Uncertainty For Other PCSK9s
Bridging The Drug Price Divide: Ideas And Approaches Debated At PSA
Industry's Rebate Arms Race: Securing Market Access At A Cost


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts